Next Article in Journal
Identification of Novel PI3Kδ Selective Inhibitors by SVM-Based Multistage Virtual Screening and Molecular Dynamics Simulations
Previous Article in Journal
miRNAs and Novel Food Compounds Related to the Browning Process
Open AccessReview

Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors

by Hui Li 1,2,3,†, Jinglin Zhang 1,2,3,†, Joanna Hung Man Tong 1,3, Anthony Wing Hung Chan 1,3, Jun Yu 2,4, Wei Kang 1,2,3,* and Ka Fai To 1,2,3,*
1
Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China
2
Institute of Digestive Disease, State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China
3
Li Ka Shing Institute of Health Science, Sir Y.K. Pao Cancer Center, The Chinese University of Hong Kong, Hong Kong, China
4
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2019, 20(23), 5999; https://doi.org/10.3390/ijms20235999
Received: 29 October 2019 / Revised: 23 November 2019 / Accepted: 25 November 2019 / Published: 28 November 2019
(This article belongs to the Section Molecular Oncology)
Colorectal cancer (CRC) is a kind of solid tumor and the third most common cancer type in the world. It is a heterogeneous disease characterized by genetic and epigenetic aberrations. The TP53 mutation is the key step driving the transition from adenoma to adenocarcinoma. The functional roles of TP53 mutation in tumor development have been comprehensively investigated. In CRC, TP53 mutation was associated with poor prognosis and chemoresistance. A gain of function (GOF) of p53 mutants promotes cell proliferation, migration and invasion through multiple mechanisms. Restoring wild type p53 function, depleting p53 mutants, or intervention by targeting the oncogenic downstreams provides potential therapeutic strategies. In this review, we comprehensively summarize the GOF of p53 mutants in CRC progression as well as in some other solid tumors, and discuss the current strategies targeting p53 mutants in malignancies. View Full-Text
Keywords: TP53; p53 mutants; colorectal cancer; solid tumor TP53; p53 mutants; colorectal cancer; solid tumor
Show Figures

Figure 1

MDPI and ACS Style

Li, H.; Zhang, J.; Tong, J.H.M.; Chan, A.W.H.; Yu, J.; Kang, W.; To, K.F. Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors. Int. J. Mol. Sci. 2019, 20, 5999.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop